Glenn Burkett Naples Corporation sold colloidal silver and supplement products as unapproved drugs, including claims to treat COVID-19.
What happened
FDA reviewed the company's websites glennburkettwellness.com and gb1com.com in November 2021, along with a linked Facebook page, and found many claims that the products treat or prevent disease. The claims covered conditions such as infections, heart disease, diabetes, Crohn's disease, depression and COVID-19, and the Colloidal Silver 1400 ppm Dropper label showed directions for use in pets with pictures of a dog and cat. FDA also said the colloidal silver products are sold over the counter even though no colloidal silver drug is recognized as safe and effective.
What FDA found
The products are sold with claims to treat or prevent disease, which makes them drugs, but they have no FDA-approved application.
FD&C Act sections 201(p), 301(d) and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]The products are meant for diseases a person cannot safely diagnose or treat alone, so they carry no adequate directions for use and are misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]Over-the-counter colloidal silver products are not generally recognized as safe and effective, so selling them without an approved application is illegal and misbrands them.
21 CFR 310.548; FD&C Act sections 505G(a)(5) and 502(ee)The Colloidal Silver 1400 ppm Dropper is promoted for pets without an approved animal drug application, which makes it unsafe and adulterated.
FD&C Act sections 512(a) and 501(a)(5) [21 U.S.C. 360b(a), 351(a)(5)]The eye drops and nasal spray are especially risky because putting a substance directly in the eye or nose can cause permanent harm such as vision loss or nasal damage.
The Silver 750 Sinus Spray and Silver Eye Drops are labeled as dietary supplements even though they are not intended to be swallowed.
FD&C Act section 201(ff)(2)(A)(i) [21 U.S.C. 321(ff)(2)(A)(i)]
What FDA wants
FDA asks the company to stop selling unapproved products that claim to treat or prevent COVID-19 right away. Within 15 working days of receiving the letter, the company must write to FDA with the specific steps taken to fix the violations and prevent them from happening again, or explain why it disagrees.
Who should pay attention
- online sellers of colloidal silver or 'natural' immune products
- retailers and marketplaces that list supplement kits with disease claims
- companies that promote products through social media testimonials
This is a summary. Read the original letter on fda.gov.